Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Masseter Reduction
NCT05309564Completed
- Sponsor
- Region Västerbotten
- Start
- Mar 2020
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of botulinum toxin type A in masseter hypertrophy (2 arms), sponsored by Region Västerbotten. Primary endpoint: Change of maximal voluntary bite force at 12 months. Started Mar 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
masseter hypertrophy
Beyond the preview
Go deeper on NCT05309564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309564.